US EditionAZ deepens Chinese ties, signs $18.5bn CSPC obesity deal
AstraZeneca's $18.5 billion deal with CSPC includes upfront and milestone payments to enhance obesity and diabetes therapies amid a market forecasted to exceed $100 billion by 2030.
7 Articles
7 Articles
AstraZeneca looks to China for obesity drug candidates
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Oh, hi. Today, we discuss delays in the launch of TrumpRx. Also, Sanofi is deprioritizing its mRNA flu vaccine. The need-to-know this morning Regeneron Pharmaceuticals expects an FDA approval decision in the first half of this year for its gene therapy to treat a rare, genetic cause of hearing loss. An application for the…
AstraZeneca concluded a licensing agreement at at US$ 4.7 bill is with the Chinese group s CSPC Pharmaceuticals to develop medications for weight loss and diabetes, seeking to expand in this market at altitudes or. Read more (01/30/2026)
AstraZeneca has agreed to pay Chinese company CSPC Pharmaceutical Group up to $18.5 billion to develop weight loss and diabetes drugs, as the British… AstraZeneca: Investing $18.5 billion in China for next generation weight loss drugs - ΙΝΑΦΤΕΜΒΟΡΙΚΙ
Coverage Details
Bias Distribution
- 67% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
